<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687843</url>
  </required_header>
  <id_info>
    <org_study_id>TMOG-GC01</org_study_id>
    <nct_id>NCT00687843</nct_id>
  </id_info>
  <brief_title>Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients</brief_title>
  <acronym>TMOG-GC01</acronym>
  <official_title>Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo Metropolitan Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokyo Metropolitan Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since it is not uncertain about efficacy of combination therapy with PSK and TS-1 in gastric&#xD;
      cancer, in this study, we compare efficacy and safety of postoperative adjuvant therapy using&#xD;
      TS-1 or TS-1+PSK in the stage II or III gastric cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TS-1 is an oral anticancer drug approved in Japan consisting of tegafur (a pro-drug of&#xD;
      fluorouracil, 5-FU), gimeracil and oteracil potassium. The response rate of TS-1 in the&#xD;
      untreated advanced gastric cancer patients was 44.6% in the late phase II study. In 2007,&#xD;
      efficacy of the adjuvant therapy using TS-1 in the resected gastric cancer patients was&#xD;
      demonstrated by ACTS-GC study group conducted in Japan. PSK is an oral anticancer drug&#xD;
      approved in Japan consisting of protein-bound polysaccharide extracted from mycelium of&#xD;
      Trametes (Coriolus) versicolor, a kind of mushroom. Even though survival benefit by PSK in&#xD;
      combination with adjuvant chemotherapy using 5-FU or tegafur in the postoperative gastric&#xD;
      cancer patients was already demonstrated, it is not uncertain about efficacy of combination&#xD;
      therapy with PSK and TS-1 in gastric cancer. In this study, we compare efficacy and safety of&#xD;
      postoperative adjuvant therapy using TS-1 or TS-1+PSK in the stage II or III gastric cancer&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Five years after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, quality of life, drug compliance, adverse events, serial changes of tumor markers</measure>
    <time_frame>Five years after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The TS-1 group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The TS-1+PSK Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-gimeracil-oteracil potassium (TS-1)</intervention_name>
    <description>80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>TS-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Krestin (PSK)</intervention_name>
    <description>3 g, PO from day 1 to day 336</description>
    <arm_group_label>2</arm_group_label>
    <other_name>PSK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who is pathologically confirmed as gastric cancer&#xD;
&#xD;
          -  Patient who has received surgery with D2 or more lymph node dissection and whose final&#xD;
             curability of surgical resection is grade A or B&#xD;
&#xD;
          -  Patient whose final stage is II (except for T1), IIIA, or IIIB&#xD;
&#xD;
          -  Patient without liver, peritoneal and distant metastasis, and who is negative in&#xD;
             peritoneal cytological diagnosis&#xD;
&#xD;
          -  Patient whose age at the registration is ranging between 20 and 80 years old&#xD;
&#xD;
          -  Patient who has not received any preoperative therapy including radiotherapy,&#xD;
             chemotherapy and immunotherapy&#xD;
&#xD;
          -  Patient who has received surgery for gastric cancer within six weeks before the&#xD;
             registration, and is judged to be capable of oral administration&#xD;
&#xD;
          -  Patient who has no serious concurrent complications, and satisfies the following&#xD;
             criteria&#xD;
&#xD;
               -  White blood cell count: &gt; LLN or &gt; 4,000 /mm3&#xD;
&#xD;
               -  Platelet count: &gt; 100,000 /mm3&#xD;
&#xD;
               -  Serum total bilirubin: &lt; 1.5 mg/dL&#xD;
&#xD;
               -  Serum AST (GOT), ALT (GPT): &lt; 2.5 * ULN&#xD;
&#xD;
               -  Serum creatinine: &lt; ULN&#xD;
&#xD;
          -  Patient who has received an explanation of this study by assent documents, and has&#xD;
             given written informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with metachronous or synchronous multicancer&#xD;
&#xD;
          -  Patient who contraindicates to TS-1&#xD;
&#xD;
          -  Patient who requires continuous use of flucytosine, phenytoin or warfarin potassium&#xD;
&#xD;
          -  Patient who has experienced serious drug allergy over grade 3 in the past&#xD;
&#xD;
          -  Patient with serious complications including paralysis of intestine, ileus,&#xD;
             interstitial pneumonitis, fibroid lung, uncontrollable diabetes mellitus, heart&#xD;
             insufficiency, renal insufficiency or hepatic insufficiency&#xD;
&#xD;
          -  Patient with diarrhea (watery stool)&#xD;
&#xD;
          -  Patient who is pregnant or in lactation, or wish to become pregnant during this study&#xD;
&#xD;
          -  Male patient who intends to make someone pregnant during this study&#xD;
&#xD;
          -  Patient with HIV positive&#xD;
&#xD;
          -  Patient who is judged to be inappropriate as subject to this study by the principal&#xD;
             investigator or the doctors in charge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masatsugu Kitamura, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.</citation>
    <PMID>17978289</PMID>
  </reference>
  <reference>
    <citation>Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994 May 7;343(8906):1122-6.</citation>
    <PMID>7910230</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>May 28, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokyo Metropolitan Oncology Group</investigator_affiliation>
    <investigator_full_name>Yoshiaki Iwasaki, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital.</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>TS-1</keyword>
  <keyword>PSK</keyword>
  <keyword>Relapse-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>polysaccharide-K</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

